Trial design
The study is taking place in three Dutch hospitals: University Medical Center Utrecht (UMC), Erasmus MC Rotterdam and UMC Groningen. A dangling protocol is the current standard of care in these hospitals. Patients are randomly assigned by a computer program to group A or B. Patients in group A start a dangling protocol on POD 7. Patients in group B can mobilize without limitations starting on POD 7 and are discharged from the hospital when possible. All patients will be seen on POD 12-15, after 5-7 weeks, 2,5-3,5 months and 5-7 months at the ward or the outpatient clinic. During these visits the complications will be evaluated. The study phases and data collection time points can be found in figure 1.
Patients in group A (dangling) at the UMC Utrecht will undergo blood tests with the use of a Point Of Care Testing (POCT) device. A drop of blood will be taken on a daily basis from both the flap and from the contralateral leg (control) and will subsequently be analyzed for pO2, pCo2 and PH levels. Moreover, all patients will be invited to fill out three short (PROMIS, EQ-5D and VAS) online questionnaires at 3 and 6 months, 1 year, 1,5 and 2 years post-operative. The in- and exclusion criteria can be found in table 1.
Study Parameters
Primary study parameter: we will investigate whether there is a significant increase in the incidence of partial flap loss in patients who did not undergo a dangling protocol (group B) versus patients who did undergo a dangling protocol (group A). We defined complete flap necrosis, partial flap necrosis (if a revision surgery with a second free flap is necessary) and pulmonary embolism as major complications. Screening for pulmonary embolism will only be performed if there is a clinical suspicion of a pulmonary embolism. Partial flap loss is defined as a minor complication if no secondary free flap is needed or as a major complication if a secondary free flap was needed. Wound dehiscence, wound infection, failure of skin graft ingrowth on the free flap, and hematoma for which a surgical exploration was needed were defined as minor complications.
Randomization
Randomization will be performed in Castor EDC, Amsterdam, the Netherlands. This study cannot be blinded. The randomization is stratified per medical center. The coordinating researcher will log in to the computer system and fill out the required information. In case of a re-intervention the patient will still be included in the study. If the arterial and/or venous anastomosis required a redo then the day of the performed re-intervention will be POD 0. The study (dangling or no-dangling protocol) will start 7 days after the re-intervention.
In case the patient has a partial or complete flap loss and a secondary free flap transplantation is indicated, the patient will not be re-invited to join the study for randomization after the secondary free flap.
Study procedures
All patients randomized to group A will undergo a dangling protocol. In table 2 this dangling protocol is further specified. The flap will be wrapped during the dangling procedure. After 5-7 weeks, 2.5-3.5 months and 5-7 months the patients will be seen at the outpatient clinic to evaluate complications. Photographs of the flap will be taken on POD 6 or 7 and at all planned follow up moments. These photos will be used in a sample test to check whether the estimated percentage partial flap necrosis and skin graft take was estimated correctly.
Patients in group B are allowed to dangle for an unlimited time starting on POD 7. Patients in group B are allowed to go home (if the wound status and further co-morbidities allow) and will be seen at the outpatient office between POD 12 and 15 (depending on the weekends) and after 5-7 weeks, 2.5-3.5 months and 5-7 months. From POD 7 until POD 14 patients will wear a step counter and they will keep track of the time they spent standing or sitting with their leg down. The flap will be wrapped starting on POD 7. During the outpatient office visits the complications will be evaluated.
Point of care blood tests
All of the randomized patients in group A at the UMC Utrecht will undergo blood tests. Using a POCT device a drop of blood from the free flap and from the contralateral “healthy” leg (control group) will be analyzed for blood gases (pO2, PCo2, PH). If the patient has a bilateral leg injury the drop of blood will be taken from a different body part. This study is designed to get a better insight into the gaseous changes within the free flap during the dangling process. Blood will be taken from the free flap and the contralateral leg at the beginning and at the end of the dangling session. Table 3 illustrates the protocol for the POCT. The goal of these POCT measurements is to present a curve of the gaseous changes during a dangling protocol and to get more insight in the effect of dangling on these blood gases.
Anticoagulant use during the study
The use of coumarines or a novel oral anticoagulant will be pre-operatively stopped. In case the patient has an indication for so called bridging with a therapeutic dose of low molecular weight heparin (LMWH) due to co-morbidities, this will be done. If bridging is not indicated, the patient will receive a prophylactic dose of LMWH to reduce the risk of deep venous thrombosis or pulmonary embolism, which is standard of care for all patients undergoing surgery in the Netherlands.
Patients who use acetylsalicylic acid will continue this medication. Acetylsalicylic acid will not be started in patients after a free flap in case the patients did not use this medication before the operation.
Sample size calculation
Based on the incidence of partial flap necrosis in the meta-analysis by Xiong et al., we performed a power calculation8. Because total free flap loss occurs rarely after POD 5, we decided to focus in this study on partial flap loss. Based on the rate of partial flap loss of 6%, we decided that an absolute increase in incidence of 12% would be clinically significant. To detect this non-inferiority margin with 80% power and a two-sided 95% confidence interval (CI) and 5% estimated lost to follow up, we aim to include 130 patients. Each year about a hundred lower limb reconstructions are performed at our three hospitals, resulting in an inclusion time of two years.
Statistical analysis
Primary hypothesis: We will calculate the absolute risk differences in incidence of partial flap loss (major and minor combined) between groups. If the upper limit of the 95% CI falls within 12% we regard this as a non-inferiority difference.
The secondary hypotheses will be tested for superiority: Absolute risk difference for one or more major complications and 95% CI, and linear regression for length of stay, physical function and blood tests.
We will perform an intention to treat analysis. However, since investigators can decide to withdraw a subject from the study in case of life threatening medical reasons (see Recruitment), we will perform an additional per protocol analysis and compare baseline characteristics of patients withdrawn and patients lost to follow-up. We will use multiple imputation to account for missing variables.
We will perform an interim analysis when 40 patients are randomized. In case we find a significant difference through Fisher exact test in patients having one or more major or minor complications, we will terminate the trial. Based on previous studies, we will test our final non-inferiority hypothesis without alpha adjustment for the superiority tested interim analysis.
Recruitment, consent and withdrawal
Patients will be invited by a plastic surgery resident who is not affiliated with this study or clinically responsible for the patient. This will be done before the POD 5. They will then have at least 24 hours’ time to decide whether they would like to join the study. The patient will be provided with an information letter and will be asked to give written informed consent. The study will start on POD 7. If a patient at the UMC Utrecht is randomized to group A and would like to take part in the study but does not want to have the POCT performed, then the patient will still remain in group A (without blood test).
Based on the current literature there are no known increased risks involved with the participation in this study. The hypothesized beneficial effect is that patients in group B might have a shorter hospital stay.
Subjects can leave the study at any time for any reason if they wish to do so, without any consequences. The investigator can decide to withdraw a subject from the study in case of life threatening medical reasons. If during the study it is anticipated there is a very high risk of total flap necrosis, the treating physician can decide to withdraw the patient from the dangling part of the study. This accounts for patients in both group A and B. This risk will be an estimation based on the clinical experience of the surgeon. For ethical reasons, we believe that this possibility is important in this study. The patient will still be included for the secondary objectives. In case a patient experiences an adverse event, which prevents the patient to adequately perform a dangling or a non-dangling protocol, the study will be terminated for the primary study outcome. If possible, the patient will still be included for the secondary objectives.
Study data management, oversight and publication
Data will be handled confidentially. Data will be collected in the electronic patient file by the local researcher and subsequently registered in Castor EDC, Amsterdam, the Netherlands. Patients will be anonymized. The handling of personal data will be performed in compliance with the Dutch Personal Data Protection Act and in compliance with Good Clinical Practice guidelines. Data will be kept for 15 years. Informed consent from study participants will be recorded at every hospital in the electronic patient file and signed paper forms will be securely locked away within the hospital where the patient is undergoing treatment.
The study is monitored by an independent monitoring company (Julius Clinical, Zeist, the Netherlands) according to a detailed monitoring plan. Insurances are provided for all participants in accordance with Dutch legislation. The results of this study will be submitted to peer-reviewed journals.